Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles

References

• Sung Y, Kim S. Recent advances in the development of gene delivery systems. Biomater Res. 2019;23:8.
   PubMedGoogle Scholar
• Weng Y, Huang Q, Li C, et al. Improved nucleic acid therapy with advanced nanoscale biotechnology. Mol Ther Nucleic Acids. 2020;19:581–601.
   PubMedGoogle Scholar
• Weng Y, Xiao H, Zhang J, Liang X-J, Huang Y. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol Adv. 2019;37:801–825.
   PubMed Web of Science ®Google Scholar
• Weng Y, Li C, Yang T, et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol Adv. 2020;40:107534.
   PubMed Web of Science ®Google Scholar
• Li H, Yang Y, Hong W, Huang M, Wu M, Zha X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020;5:1.
   PubMed Web of Science ®Google Scholar
• Wong JKL, Mohseni R, Hamidieh AA, MacLaren RE, Habib N, Seifalian AM. Will nanotechnology bring new hope for gene delivery? Trends Biotechnol. 2017;35:434–451. doi:10.1016/j.tibtech.2016.12.009
   PubMed Web of Science ®Google Scholar
• Bulcha JT, Wang Y, Ma H, et al. Viral vector platforms within the gene therapy landscape. Sig Transduct Target Ther. 2021;6:53.
   PubMed Web of Science ®Google Scholar
• Wolf J, Bruno S, Eichberg M, et al. Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens. Npj Vaccines. 2020;5:51. doi:10.1038/s41541-020-0204-7
   PubMed Web of Science ®Google Scholar
• Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA. Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Adv Drug Del Rev. 2021;170:113–141.
   PubMed Web of Science ®Google Scholar
• Yang D. Application of nanotechnology in the COVID-19 pandemic. Int J Nanomed. 2021;16:623–649. doi:10.2147/IJN.S296383
   PubMed Web of Science ®Google Scholar
• Park KS, Sun X, Aikins ME, Moon JJ. Non-viral COVID-19 vaccine delivery systems. Adv Drug Deliv Rev. 2021;169:137–151. doi:10.1016/j.addr.2020.12.008
   PubMed Web of Science ®Google Scholar
• Urits I, Swanson D, Swett MC, et al. A review of patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther. 2020;9:301–315. doi:10.1007/s40120-020-00208-1
   PubMed Web of Science ®Google Scholar
• Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Sig Transduct Target Ther. 2020;5:101.
   PubMed Web of Science ®Google Scholar
• Wang Y, Bruggeman KF, Franks S. Is viral vector gene delivery more effective using biomaterials? Adv Healthc Mater. 2021;10:2001238. doi:10.1002/adhm.202001238
   PubMed Web of Science ®Google Scholar
• Rai R, Alwani S, Badea I. Polymeric nanoparticles in gene therapy: new avenues of design and optimization for delivery applications. Polymers. 2019;11:745. doi:10.3390/polym11040745
   PubMed Web of Science ®Google Scholar
• Caccamo D, Currò M, Ientile R, et al. Intracellular fate and impact on gene expression of doxorubicin/cyclodextrin-graphene nanomaterials at sub-toxic concentration. Int J Mol Sci. 2020;21:4891. doi:10.3390/ijms21144891
   PubMedGoogle Scholar
• Piperno A, Mazzaglia A, Scala A, et al. Casting light on intracellular tracking of a new functional graphene-based microrna delivery system by FLIM and raman imaging. ACS Appl Mater Interfaces. 2019;11:46101–46111. doi:10.1021/acsami.9b15826
   PubMedGoogle Scholar
• Mazzaglia A, Scala A, Sortino G, et al. Intracellular trafficking and therapeutic outcome of multiwalled carbon nanotubes modified with cyclodextrins and polyethylenimine. Colloids Surf B Biointerfaces. 2018;163:55–63. doi:10.1016/j.colsurfb.2017.12.028
   PubMed Web of Science ®Google Scholar
• Elmowafy EM, Tiboni M, Soliman ME. Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic‑co‑glycolic acid) micro and nanoparticles. J Pharm Investig. 2019;49:347–380. doi:10.1007/s40005-019-00439-x
   Google Scholar
• Scala A, Piperno A, Micale N, et al. “Click” on PLGA-PEG and hyaluronic acid: gaining access to anti-leishmanial pentamidine bioconjugates. J Biomed Mater Res B Appl Biomater. 2018;106:2778–2785.
   PubMedGoogle Scholar
• Fazio E, Scala A, Grimato S, Ridolfo A, Grassi G, Neri F. Laser light triggered smart release of silibinin from a PEGylated–PLGA gold nanocomposite. J Mater Chem B. 2015;3:9023–9032.
   PubMedGoogle Scholar
• Mineo PG, Foti C, Vento F, et al. Salinomycin-loaded PLA nanoparticles: drug quantification by GPC and wave voltammetry and biological studies on osteosarcoma cancer stem cells. Anal Bioanal Chem. 2020;412:4681–4690. doi:10.1007/s00216-020-02721-6
   PubMedGoogle Scholar
• Liénard R, Montesi M, Panseri S, et al. Design of naturally inspired jellyfish-shaped cyclo-polylactides to manage osteosarcoma cancer stem cells fate. Mater Sci Eng C. 2020;117:111291. doi:10.1016/j.msec.2020.111291
   PubMedGoogle Scholar
• Lee PW, Pokorski JK. Poly(lactic-co-glycolic acid) devices: production and applications for sustained protein delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018;10:e1516. doi:10.1002/wnan.1516
   PubMed Web of Science ®Google Scholar
• Zhao J, Weng G, Li J, Zhu J, Zhao J. Polyester-based nanoparticles for nucleic acid delivery. Mater Sci Eng C. 2018;92:983–994. doi:10.1016/j.msec.2018.07.027
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101–124.
   PubMed Web of Science ®Google Scholar
• Onoue S, Yamada S, Chan H. Nanodrugs: pharmacokinetics and safety. Int J Nanomedicine. 2014;9:1025–1037. doi:10.2147/IJN.S38378
   PubMed Web of Science ®Google Scholar
• Kemp JA, Shim MS, Heo CY, Kwon YJ. “Combo” nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv Drug Deliv Rev. 2016;98:3–18.
   PubMed Web of Science ®Google Scholar
• Jin M, Jin G, Kang L, Chen L, Gao Z, Huang W. Smart polymeric nanoparticles with pH-responsive and PEG -detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes. Int J Nanomedicine. 2018;13:2405–2426. doi:10.2147/IJN.S161426
   PubMed Web of Science ®Google Scholar
• Xu C-F, Iqbal S, Shen S, Luo Y-L, Yang X, Wang J. Development of “CLAN” nanomedicine for nucleic acid therapeutics. Small. 2019;15(16):1900055. doi:10.1002/smll.201900055
   Google Scholar
• Ashrafizadeh M, Delfi M, Hashemi F, et al. Biomedical application of chitosan-based nanoscale delivery systems: potential usefulness in siRNA delivery for cancer therapy. Carbohydr Polym. 2021;260:117809.
   PubMed Web of Science ®Google Scholar
• Mirzaei S, Mahabady MK, Zabolian A, et al. Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: current status with an emphasis on delivery systems. Life Sci. 2021;275:119368. doi:10.1016/j.lfs.2021.119368
   PubMed Web of Science ®Google Scholar
• Mirzaei S, Gholami MH, Hashemi F, et al. Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: approaching to a new era of cancer chemotherapy. Life Sci. 2021;277:119430.
   PubMed Web of Science ®Google Scholar
• Dana H, Chalbatani GM, Habibollah M. Molecular mechanisms and biological functions of siRNA. Int J Biomed Sci. 2017;13:48–57.
   PubMedGoogle Scholar
• Saw PE, Song EW. siRNA therapeutics: a clinical reality. Sci China Life Sci. 2020;63:485–500. doi:10.1007/s11427-018-9438-y
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15:541–555. doi:10.1038/nrg3763
   PubMed Web of Science ®Google Scholar
• Nikam RR, Gore KR. Journey of siRNA: clinical developments and targeted delivery. Nucleic Acid Ther. 2018;28:209–224. doi:10.1089/nat.2017.0715
   PubMed Web of Science ®Google Scholar
• Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20:1–16. doi:10.1002/jgm.3015
   Google Scholar
• Lundstrom K. Are viral vectors any good for RNAi antiviral therapy? Viruses. 2020;12:8–13.
   Google Scholar
• Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28:109–118. doi:10.1089/nat.2018.0736
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Hushmandi K, Rahmani Moghadam E, et al. Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer. Bioengineering. 2020;7:91. doi:10.3390/bioengineering7030091
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. Progress in natural compounds/siRNA Co-delivery employing nanovehicles for cancer therapy. ACS Comb Sci. 2020;22:669–700. doi:10.1021/acscombsci.0c00099
   PubMed Web of Science ®Google Scholar
• Taxman DJ, Moore CB, Guthrie EH, Huang MTH. Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. In: Sioud M, editor. RNA Therapeutics. Methods in Molecular Biology (Methods and Protocols). Vol. 629. Humana Press; 2010.
   Google Scholar
• Acharya R. The recent progresses in shRNA-nanoparticle conjugate as a therapeutic approach. Mater Sci Eng C. 2019;104:109928. doi:10.1016/j.msec.2019.109928
   PubMedGoogle Scholar
• Li H, Wang Z, Zhang J, et al. Enhanced shRNA delivery by the combination of polyethylenimine, ultrasound, and nanobubbles in liver cancer. Technol Health Care. 2019;27(S1):263–272. doi:10.3233/THC-199025
   PubMedGoogle Scholar
• Wang L, Cho KB, Li Y, Tao G, Xie Z, Guo B. Long noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer. Int J Mol Sci. 2019;20:5758. doi:10.3390/ijms20225758
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–3981. doi:10.1158/0008-5472.CAN-16-2634
   PubMed Web of Science ®Google Scholar
• Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting noncoding RNAs in disease. J Clin Invest. 2017;127:761–771. doi:10.1172/JCI84424
   PubMed Web of Science ®Google Scholar
• Matsui M, Corey D. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017;16:167–179. doi:10.1038/nrd.2016.117
   PubMed Web of Science ®Google Scholar
• Rao Y, Fang Y, Tan W, et al. Delivery of long non-coding RNA NEAT1 by peripheral blood monouclear cells-derived exosomes promotes the occurrence of rheumatoid arthritis via the MicroRNA-23a/MDM2/SIRT6 axis. Front Cell Dev Biol. 2020;8:952. doi:10.3389/fcell.2020.551681
   Google Scholar
• Koscianska E, Starega-Roslan J, Krzyzosiak WJ. The role of dicer protein partners in the processing of microrna precursors. PLoS One. 2011;6:e28548. doi:10.1371/journal.pone.0028548
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNA target recognition and regulatory functions. Cell. 2009;136:215–233. doi:10.1016/j.cell.2009.01.002
   PubMed Web of Science ®Google Scholar
• Bernardo BC, Ooi JYY, Lin RCY, Mcmullen JR. miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart. Future Med Chem. 2015;7:1771–1792. doi:10.4155/fmc.15.107
   PubMed Web of Science ®Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141:1202–1207. doi:10.1016/j.jaci.2017.08.034
   PubMed Web of Science ®Google Scholar
• O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018;9:402. doi:10.3389/fendo.2018.00402
   PubMed Web of Science ®Google Scholar
• Ganju A, Khan S, Hafeez BB, et al. miRNA nanotherapeutics for cancer. Drug Discov Today. 2017;22:424–432. doi:10.1016/j.drudis.2016.10.014
   PubMed Web of Science ®Google Scholar
• Wu M, Wang G, Tian W, Deng Y, Xu Y. MiRNA-based therapeutics for lung cancer. Curr Pharm Des. 2018;23:5989–5996. doi:10.2174/1381612823666170714151715
   PubMed Web of Science ®Google Scholar
• Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27:710–728. doi:10.1016/j.ymthe.2019.02.012
   PubMed Web of Science ®Google Scholar
• Zarghampoor F, Azarpira N, Khatami SR, Behzad-Behbahani A, Foroughmand AM. Improved translation efficiency of therapeutic mRNA. Gene. 2019;707:231–238. doi:10.1016/j.gene.2019.05.008
   PubMed Web of Science ®Google Scholar
• Zhou L, Qin Z, Zhu Y, He Z, Xu T. Current RNA-based therapeutics in clinical trials. Curr Gene Ther. 2019;19:172–196. doi:10.2174/1566523219666190719100526
   PubMed Web of Science ®Google Scholar
• Guan S, Rosenecker J. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 2017;24:133–143. doi:10.1038/gt.2017.5
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr Opin Immunol. 2020;65:14–20. doi:10.1016/j.coi.2020.01.008
   PubMed Web of Science ®Google Scholar
• Kumar A, Dowling WE, Gómez Román R, et al. Status report on COVID-19 vaccines development. Curr Infect Dis. 2021;23:9. doi:10.1007/s11908-021-00752-3
   PubMedGoogle Scholar
• Buck J, Grossen P, Cullis PR, Huwyler J, Witzigmann D. Lipid-based DNA therapeutics: hallmarks of non-viral gene delivery. ACS Nano. 2019;13:3754–3782. doi:10.1021/acsnano.8b07858
   PubMed Web of Science ®Google Scholar
• Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273–288. doi:10.1146/annurev-med-012017-043332
   PubMed Web of Science ®Google Scholar
• Shi B, Zheng M, Tao W, et al. Challenges in DNA delivery and recent advances in multifunctional polymeric DNA delivery systems. Biomacromol. 2017;18:2231–2246. doi:10.1021/acs.biomac.7b00803
   PubMed Web of Science ®Google Scholar
• Wahane A, Waghmode A, Kapphahn A, Dhuri K, Gupta A, Bahal R. Role of lipid-based and polymer-based non-viral vectors in nucleic acid delivery for next-generation gene therapy. Molecules. 2020;25:2866. doi:10.3390/molecules25122866
   PubMed Web of Science ®Google Scholar
• Nayerossadat N, Maedeh T, Ali PA. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res. 2012;1:27. doi:10.4103/2277-9175.98152
   PubMedGoogle Scholar
• Keeler AM, Flotte TR. Recombinant adeno-associated virus gene therapy in light of luxturna (and zolgensma and glybera): where are we, and how did we get here? Annu Rev Virol. 2019;6:601–621. doi:10.1146/annurev-virology-092818-015530
   PubMed Web of Science ®Google Scholar
• Atasheva S, Shayakhmetov DM. Oncolytic viruses for systemic administration: engineering a whole different animal. Mol Ther. 2021;29:904–907. doi:10.1016/j.ymthe.2021.02.001
   PubMedGoogle Scholar
• Howells A, Marelli G, Lemoine NR, Wang Y. Oncolytic virus-interaction of virus and tumor cells in the battle to eliminate cancer. Front Oncol. 2017;7:195. doi:10.3389/fonc.2017.00195
   PubMed Web of Science ®Google Scholar
• Donnelley M, Parsons DW. Gene therapy for cystic fibrosis lung disease: overcoming the barriers to translation to the clinic. Front Pharmacol. 2018;9:1381. doi:10.3389/fphar.2018.01381
   PubMed Web of Science ®Google Scholar
• Brescia M, Janssen JM, Liu J, Goncalves MAFV. High-capacity adenoviral vectors permit robust and versatile testing of DMD gene repair tools and strategies in human cells. Cells. 2020;9:869. doi:10.3390/cells9040869
   PubMedGoogle Scholar
• Li Z, Ho W, Bai X, Li F, Chen Y-J, Zhang X-Q XX. Nanoparticle depots for controlled and sustained gene delivery. J Contr Rel. 2020;322:622–631. doi:10.1016/j.jconrel.2020.03.021
   PubMedGoogle Scholar
• Huang D, Cao Y, Yang X, et al. A nanoformulation-mediated multifunctional stem cell therapy with improved beta-amyloid clearance and neural regeneration for alzheimer’s disease. Adv Mater. 2021;33:2006357. doi:10.1002/adma.202006357
   Google Scholar
• Proulx J, Joshi C, Vijayaraghavalu S, et al. Arginine-modified polymers facilitate poly (lactide-co-glycolide)-based nanoparticle gene delivery to primary human astrocytes. Int J Nanomed. 2020;15:3639–3647. doi:10.2147/IJN.S250865
   PubMed Web of Science ®Google Scholar
• Liu C, Xie Y, Li X, et al. Folic acid/peptides modified PLGA-PEI-PEG polymeric vectors as efficient gene delivery vehicles: synthesis, characterization and their biological performance. Mol Biotechnol. 2021;63:63–79. doi:10.1007/s12033-020-00285-5
   PubMed Web of Science ®Google Scholar
• Sukumar UK, Rajendran JCB, Gambhir SS, Massoud TF, Paulmurugan R. SP94-targeted triblock copolymer nanoparticle delivers thymidine kinase-p53-nitroreductase triple therapeutic gene and restores anticancer function against hepatocellular carcinoma in vivo. ACS Appl Mater Interfaces. 2020;12:11307–11319. doi:10.1021/acsami.9b20071
   PubMedGoogle Scholar
• Devulapally R, Lee T, Barghava-Shah A, et al. Ultrasound-guided delivery of thymidine kinase-nitroreductase dual therapeutic genes by PEGylated-PLGA/PIE nanoparticles for enhanced triple negative breast cancer therapy. Nanomedicine. 2018;13:1051–1066. doi:10.2217/nnm-2017-0328
   PubMedGoogle Scholar
• Hazekawa M, Nishinakagawa T, Kawakubo-Yasukochi T, Nakashima M. Glypican-3 gene silencing for ovarian cancer using siRNA-PLGA hybrid micelles in a murine peritoneal dissemination model. J Pharmacol Sci (Amsterdam, Netherlands). 2019;139:231–239.
   PubMedGoogle Scholar
• Chen Z, Liang Y, Feng X, et al. Vitamin-B12-conjugated PLGA-PEG nanoparticles incorporating miR-532-3p induce mitochondrial damage by targeting apoptosis repressor with caspase recruitment domain (ARC) on CD320-overexpressed gastric cancer. Mater Sci Eng C. 2021;120:111722. doi:10.1016/j.msec.2020.111722
   PubMed Web of Science ®Google Scholar
• Lin WJ, Lee WC. Polysaccharide-modified nanoparticles with intelligent CD44 receptor targeting ability for gene delivery. Int J Nanomed. 2018;13:3989–4002. doi:10.2147/IJN.S163149
   PubMed Web of Science ®Google Scholar
• Yu M, Wang K, Han Z, et al. DOTAP-incorporated PEG-PLGA nanoparticles for efficient in vitro and in vivo gene delivery. J Biomed Nanotechnol. 2018;14:281–293. doi:10.1166/jbn.2018.2470
   PubMedGoogle Scholar
• Zhao G, Liu A, Zhang Y, et al. Nanoparticle-delivered siRNA targeting Bruton’s tyrosine kinase for rheumatoid arthritis therapy. Biomater Sci. 2019;7:4698–4707. doi:10.1039/C9BM01025D
   PubMedGoogle Scholar
• Luo YL, Xu CF, Li HJ, et al. Macrophage-specific in vivo gene editing using cationic lipid-assisted polymeric nanoparticles. ACS Nano. 2018;12:994–1005. doi:10.1021/acsnano.7b07874
   PubMed Web of Science ®Google Scholar
• Fan YN, Li M, Luo YL, et al. Cationic lipid-assisted nanoparticles for delivery of mRNA cancer vaccine. Biomater Sci. 2018;6:3009–3018. doi:10.1039/C8BM00908B
   PubMed Web of Science ®Google Scholar
• Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20:41. doi:10.1186/s12943-021-01335-5
   PubMed Web of Science ®Google Scholar
• Chen Q, Gao M, Li Z, et al. Biodegradable nanoparticles decorated with different carbohydrates for efficient macrophage-targeted gene therapy. J Contr Rel. 2020;323:179–190. doi:10.1016/j.jconrel.2020.03.044
   PubMedGoogle Scholar
• Katebi A, Varshochian R, Riazirad F, Ganjalikhani-Hakemi M, Ajdary S. Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major infected-macrophages activation. Biomed Pharmacother. 2021;137:111276. doi:10.1016/j.biopha.2021.111276
   PubMedGoogle Scholar
• Hao X, Li Q, Wang H, et al. Red-blood-cell-mimetic gene delivery systems for long circulation and high transfection efficiency in ECs. J Mater Chem B Mater Biol Med. 2018;6:5975–5985. doi:10.1039/C8TB01789A
   PubMed Web of Science ®Google Scholar
• Zhou YL, Yang QQ, Yan YY, et al. Gene-loaded nanoparticle-coated sutures provide effective gene delivery to enhance tendon healing. Mol Ther. 2019;27:1534–1546. doi:10.1016/j.ymthe.2019.05.024
   PubMedGoogle Scholar
• Yang QQ, Shao YX, Zhang LZ, Zhou YL. Therapeutic strategies for flexor tendon healing by nanoparticle-mediated co-delivery of bFGF and VEGFA genes. Colloids Surf B. 2018;164:165–176. doi:10.1016/j.colsurfb.2018.01.031
   PubMedGoogle Scholar
• Shi R, Lian W, Han S, et al. Nanosphere-mediated co-delivery of VEGF-A and PDGF-B genes for accelerating diabetic foot ulcers healing in rats. Gene Ther. 2018;25:425–438. doi:10.1038/s41434-018-0027-6
   PubMed Web of Science ®Google Scholar
• Amani A, Alizadeh MR, Yaghoubi H, Ebrahimi H. Design and fabrication of novel multi-targeted magnetic nanoparticles for gene delivery to breast cancer cells. J Drug Deliv Sci Technol. 2021;61:102151. doi:10.1016/j.jddst.2020.102151
   Google Scholar
• Liu X, Wang B, Li Y, et al. Powerful anticolon tumor effect of targeted gene immunotherapy using folate-modified nanoparticle delivery of CCL19 to activate the immune system. ACS Cent Sci. 2019;5:277–289. doi:10.1021/acscentsci.8b00688
   PubMedGoogle Scholar
• Liu X, Li Y, Sun X, et al. Powerful anti-colon cancer effect of modified nanoparticle-mediated IL-15 immunogene therapy through activation of the host immune system. Theranostics. 2018;8:3490–3503. doi:10.7150/thno.24157
   PubMedGoogle Scholar
• Liu X, Gao X, Zheng S, et al. Modified nanoparticle mediated IL-12 immunogene therapy for colon cancer. Nanomedicine (New York, NY, United States). 2017;13:1993–2004.
   Google Scholar
• Wu T, Cai Y, Zhao X, et al. Synthesis and characterization of poly(ethylene oxide)/polylactide/polylysine tri-arm star copolymers for gene delivery. J Polym Sci a Polym Chem. 2018;56:635–644. doi:10.1002/pola.28938
   Google Scholar
• Xu C, Li D, Cao Z, Xiong M, Yang X, Wang J. Facile hydrophobization of siRNA with anticancer drug for non-cationic nanocarrier-mediated systemic delivery. Nano Lett. 2019;19:2688–2693. doi:10.1021/acs.nanolett.9b00657
   PubMedGoogle Scholar
• Xu X, Wan T, Xin H, et al. Delivery of CRISPR/Cas9 for therapeutic genome editing. J Gene Med. 2019;21:e3107. doi:10.1002/jgm.3107
   PubMed Web of Science ®Google Scholar
• Wan T, Niu D, Wu C, Xu FJ, Church G, Ping Y. Material solutions for delivery of CRISPR/Cas‐based genome editing tools: current status and future outlook. Mater Today. 2019;26:40‐66. doi:10.1016/j.mattod.2018.12.003
   Google Scholar
• Hendel A, Bak RO, Clark JT, et al. Chemically modified guide RNAs enhance CRISPR‐Cas genome editing in human primary cells. Nat Biotechnol. 2015;33:985‐989. doi:10.1038/nbt.3290
   PubMedGoogle Scholar
• Xu CF, Chen GJ, Luo YL, et al. Rational designs of in vivo CRISPR-Cas delivery systems. Adv Drug Del Rev. 2021;168:3–29. doi:10.1016/j.addr.2019.11.005
   PubMed Web of Science ®Google Scholar
• Xu C, Lu Z, Luo Y, et al. Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases. Nat Commun. 2018;9:4092. doi:10.1038/s41467-018-06522-5
   PubMedGoogle Scholar
• Zhang Y, Shen S, Zhao G, et al. In situ repurposing of dendritic cells with CRISPR/Cas9-based nanomedicine to induce transplant tolerance. Biomaterials. 2019;217:119302. doi:10.1016/j.biomaterials.2019.119302
   PubMed Web of Science ®Google Scholar
• Luo YL, Liang LF, Gan YJ, et al. An all-in-one nanomedicine consisting of CRISPR-Cas9 and an autoantigen peptide for restoring specific immune tolerance. ACS Appl Mater Interfaces. 2020;12:48259–48271. doi:10.1021/acsami.0c10885
   PubMedGoogle Scholar
• Zhang S, Shen J, Li D, Cheng Y. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing. Theranostics. 2021;11:614–648. doi:10.7150/thno.47007
   PubMed Web of Science ®Google Scholar
• Cordaro A, Neri G, Sciortino MT, Scala A, Piperno A. Graphene-based strategies in liquid biopsy and in viral diseases diagnosis. Nanomaterials. 2020;10:1014. doi:10.3390/nano10061014
   Google Scholar
• Guglielmi G. First CRISPR test for the coronavirus approved in the United States. Nature News; 2020. Available from: www.nature.com/articles/d41586-020-01402-9. Accessed August 12, 2021.
   Google Scholar
• Abbott TR, Dhamdhere G, Liu Y, et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell. 2020;181:865–876. doi:10.1016/j.cell.2020.04.020
   PubMed Web of Science ®Google Scholar
• Lotfi M, Rezaei N. CRISPR/Cas13: a potential therapeutic option of COVID-19. Biomed Pharmacother. 2020;131:110738. doi:10.1016/j.biopha.2020.110738
   PubMed Web of Science ®Google Scholar
• Poduri R, Joshi G, Jagadeesh G. Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19. Cell Signal. 2020;74:109721. doi:10.1016/j.cellsig.2020.109721
   PubMed Web of Science ®Google Scholar
• Citarella A, Scala A, Piperno A, Micale N. SARS-CoV-2 Mpro: a potential target for peptidomimetics and small-molecule inhibitors. Biomolecules. 2021;11:607. doi:10.3390/biom11040607
   PubMed Web of Science ®Google Scholar
• Mansourabadi AH, Sadeghalvad M, Mohammadi-Motlagh HR, Rezaei N. The immune system as a target for therapy of SARS-CoV-2: a systematic review of the current immunotherapies for COVID-19. Life Sci. 2020;258:118185. doi:10.1016/j.lfs.2020.118185
   PubMed Web of Science ®Google Scholar
• Malik JA, Mulla AH, Farooqi T, Pottoo FH, Anwar S, Rengasamy KRR. Targets and strategies for vaccine development against SARS-CoV-2. Biomed Pharmacother. 2021;137:111254. doi:10.1016/j.biopha.2021.111254
   PubMed Web of Science ®Google Scholar
• Machhi J, Shahjin F, Das S, et al. Nanocarrier vaccines for SARS-CoV-2. Adv Drug Del Rev. 2021;171:215–239.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–593. doi:10.1038/s41586-020-2639-4
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Nadine G. Rouphael, An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383:1920–1931. doi:10.1056/NEJMoa2022483
   PubMed Web of Science ®Google Scholar
• World Health Organization. Background document on the mRNA vaccine BNT162b2 (‎Pfizer-BioNTech)‎ against COVID-19, 2021. Available from: https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19. Accessed August 12, 2021.
   Google Scholar
• Belete TM. Review on up-to-date status of candidate vaccines for COVID-19 disease. Infect Drug Resist. 2021;14:151–161. doi:10.2147/IDR.S288877
   PubMed Web of Science ®Google Scholar
• Kim J, Eygeris Y, Gupta M, Sahay G. Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021;170:83–112.
   PubMed Web of Science ®Google Scholar
• Schoenmaker L, Witzigmann D, Kulkarni JA, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021;601:120586. doi:10.1016/j.ijpharm.2021.120586
   PubMed Web of Science ®Google Scholar
• Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: the status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2021;170:1–25.
   PubMed Web of Science ®Google Scholar
• Lim M, Badruddoza AZM, Firdous J, et al. Engineered nanodelivery systems to improve DNA vaccine technologies. Pharmaceutics. 2020;12:30. doi:10.3390/pharmaceutics12010030
   PubMed Web of Science ®Google Scholar
• Malyala P, O’Hagan DT. Chapter 12 - polymeric particles as vaccine delivery systems. In: Virgil EJC, Schijns DT, O’Hagan, editors. Immunopotentiators in Modern Vaccines. 2nd ed. Academic Press; 2017:231–248.
   Google Scholar
• Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, Martinez-Chapa SO. Nanotechnology for COVID-19: therapeutics and vaccine research. ACS Nano. 2020;14:7760–7782. doi:10.1021/acsnano.0c04006
   PubMed Web of Science ®Google Scholar
• Lin LC-W, Huang CY, Yao B-Y, et al. Viromimetic STING agonist-loaded hollow polymeric nanoparticles for safe and effective vaccination against middle east respiratory syndrome coronavirus. Adv Funct Mater. 2019;29:1807616. doi:10.1002/adfm.201807616
   PubMed Web of Science ®Google Scholar
• Medhi R, Srinoi P, Ngo N, Tran H-V, Lee TR. Nanoparticle-based strategies to combat COVID-19. ACS Appl Nano Mater. 2020;3:8557–8580. doi:10.1021/acsanm.0c01978
   Web of Science ®Google Scholar
• Vaccines Guidance Document. Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. Available from: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_16Feb2021.pdf. Accessed April 30, 2021.
   Google Scholar
• Burger L. Healthcare & Pharmaceuticals. CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/curevacs-covid-19-vaccine-misses-efficacy-goal-mass-trial-2021-06-16. Accessed August 12, 2021.
   Google Scholar
• CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV (press release). Available from: https://www.curevac.com/en/2021/06/16/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/. Accessed August 12, 2021.
   Google Scholar